U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Trump Announces U.S.–India Trade Deal Cutting Tariffs, Boosting Markets and Energy Ties 
Dollar Holds Firm as Strong U.S. Data, Fed Expectations and Global Central Bank Moves Shape Markets 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Japan Finance Minister Defends PM Takaichi’s Remarks on Weak Yen Benefits 
U.S. Stock Futures Slip as Markets Brace for Big Tech Earnings and Key Data 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
China and Uruguay Strengthen Strategic Partnership Amid Shifting Global Order 
Sandoz launches as an independent entity on the SIX Swiss Exchange, equipped with a robust credit profile and a bright growth trajectory in the generics and biosimilars industry.
Dawn of a New Era
The separation from former parent company Novartis marks a new era for Sandoz, the global leader in generic and biosimilar medicines. Chairman Gilbert Ghostine emphasized that while the company is independent, its purpose remains unchanged: pioneering access to quality medicines for patients worldwide, Korea Bizwire reported.
According to the Sandoz website, CEO Richard Saynor outlined six strategic levers driving the company's long-term value during the Sandoz Capital Markets Day. These include capitalizing on market fundamentals, maintaining leadership and scale, pursuing multiple growth drivers, improving margins, accelerating cash generation, and nurturing a compelling sustainability story.
Unwavering Commitment to Pioneering Access
Sandoz actively shapes the global healthcare environment by delivering significant annual savings of over USD 17 billion in Europe and the US alone. With a strong presence in over 100 countries, the company reaches approximately 500 million patients annually, generating an estimated total social impact of USD 180 billion annually.
As an independent company, Sandoz is fully enabled to execute its purpose-driven strategy. Focused on sustainable leadership within the generics and biosimilars industry, Sandoz is poised to make an even greater impact on global healthcare systems.
Accelerating Profitable Growth
Sandoz is well-positioned for continued profitable growth with its inclusion in market indices and investment-grade credit rating. The company's commitment to innovation, quality, and accessibility ensures its role as a global leader and European champion in the generic and biosimilar medicines sector.
Sandoz's dedication to making quality medicines available to more people in more places exemplifies its pursuit of novel delivery methods. By leveraging technology and innovation, the company aims to expand access and address unmet healthcare needs on a global scale.
Generics and biosimilars account for an estimated 80% of medicines used worldwide by volume, at about 25% of the total cost. Despite strong competitive pressures, the industry is set to grow steadily over the next decade, driven by underlying demand for these system-critical medicines.
Photo: Online Marketing/Unsplash
